• Study of Apitegromab Treatment in Children Under 2 Years Old with Spinal Muscular Atrophy (SMA)

    Recruiting

    2 1 1
    Investigated Drugs:
    Belgium France Italy The Netherlands Spain

  • Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Italy The Netherlands Norway Spain

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium France Germany Italy The Netherlands +1

  • Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Greece Italy Spain

  • Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer’s disease patients: Long-term safety evaluation

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Croatia Czechia France Greece Hungary +5

  • Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    France

  • Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    Austria France Germany Greece Italy Poland +4

  • Study of ALXN2350 gene therapy in adults with BAG3 mutation-associated dilated cardiomyopathy: A safety and efficacy trial

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Germany Italy Spain

powered by